COSTA MESA, California – 23 October 2003 – OKTO Ophtho, the premier developer and distributor of specialty technologies for eye surgery, will participate as an exhibitor at the upcoming American Academy of Ophthalmology meeting in Anaheim.
OKTO Ophtho to Exhibit at the American Academy of Ophthalmology Meeting in Anaheim
In addition to exhibiting at the main exhibit hall on November 15th through 18th, OKTO will also present its technologies at the American Academy of Oculoplastic and Reconstructive Surgeons (ASOPRS) and the "Under Pressure" Glaucoma meetings on November 13th and 14th.
OKTO's state-of-the-art, multi-media exhibit will display its core technologies for eye surgery: AmbioDry™ Amniotic Membrane Allografts and SutureGroove™ Gold Eyelid Weight Implants
AmbioDry Allografts, processed tissue grafts derived from human placenta, are employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. AmbioDry Allografts are procured, tested and processed in the United States.
In comparison to competitive tissue options, the advantages of the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life storage; prepares in minutes for surgery; substrate-free; consistent tissue quality.
SutureGroove Gold Eyelid Weights are employed by oculoplastic surgeons for the treatment of lagophthalmos. The proprietary SutureGroove technology, licensed by OKTO from AMI, incorporates suture fixation channels within the gold weight for perfected implant placement and improved patient cosmesis.
Founded in 2000, OKTO Ophtho develops and commercializes specialized,
leading-edge surgical technologies for eye surgery. OKTO’s
purpose is to develop surgical solutions that improve the quality
of life for patients, elevate the performance and productivity of
eye care professionals, and lower costs to the provider.
OKTO currently holds leadership positions with surgical devices
for oculoplastic surgeries and bio-implant technologies for ocular
surface/ophthalmic reconstructive surgeries.